Alume Biosciences is a biotechnology company developing nerve-targeted pharmaceuticals for surgical and therapeutic use.
Alume Biosciences has raised $3.6M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2025.
Alume Biosciences's investors include National Institute of Neurological Disorders and Stroke, Daniel M. Bradbury, Chrysa Mineo.
Alume Biosciences is headquartered in San Diego, United States.
Alume Biosciences is a biotechnology company developing nerve-targeted pharmaceuticals for surgical and therapeutic use.
Alume Biosciences is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alume Biosciences — Funding & Investors." VCBacked, October 30, 2025, https://www.vcbacked.co/company/alume-biosciences. Accessed August 15, 2026.
VCBacked. (2025). Alume Biosciences — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/alume-biosciences
{{cite web |title=Alume Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/alume-biosciences |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated